Published in Health Business Week, March 10th, 2006
Hematide, a synthetic, peptide-based, next-generation erythropoiesis-stimulating agent (ESA), is designed to stimulate the production of red blood cells. It is currently being evaluated in four phase II clinical trials in the United States and Europe to treat anemia in chronic kidney disease (CKD) and cancer patients.
Pursuant to the agreement, Takeda will pay to Affymax US$17 million as an up-front payment and will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.